Mon, Mar 2, 2015, 11:48 AM EST - U.S. Markets close in 4 hrs 12 mins

Recent

% | $
Quotes you view appear here for quick access.

BioTime, Inc. Message Board

  • SortNewest  |  Oldest  |  Most Replied Expand all replies
    • and this is worth 8 dollars a share ? TELL ME YOU JEST Total revenue (including royalties from product sales and other revenue, revenue recognition of deferred license fees and grant income) was $1.4M. License fees were $88.2K; royalties were $201.6K and grant income logged in at $1.13M. The increase in revenue is primarily attributable to receipt of the QTPD grant and sales of research products. R&D expenses were $3.5M increasing 230% year-over-year in Q4/10 due to increased investment in R&D relating to candidate stem cell therapeutic products. G&A logged in at $1.7M. There was an $899.7K foreign currency gain. There was also a net profit of $753K gain from non-controlling interest attributing a comprehensive net loss of $2.07M. Total expense was $5.17M with the loss from operations at $3.72M based on weighted average basic and diluted common shares of 46.9M.

      Cash and cash equivalents totaled $33.3M as of 12/31/10
      For FY10, total revenue (including royalties from product sales and other revenue, revenue recognition of deferred license fees and grant income) was $3.7M, up 91% from $1.9M in 2009. The increase in revenue is primarily attributable to receipt of $1.6M of $4.7M research grant from CIRM, the recognition of the $733K grant awarded to us under the QTDP, and a $106K increase in the sale of research products offset by a slight decrease in royalties from the sale of Hextend®, BTX’s proprietary physiologically balanced blood plasma volume expander used in surgery and trauma care. Total expense for FY10 was $13.5M, compared to $5.4M for FY09. Increased total expense in 2010 over 2009 primarily reflects the greater amount of grant-funded research and development work during 2010 compared to 2009, as well as additional R&D expense incurred by new subsidiaries acquired or launched during 2010. Net loss attributable for FY10 was $11.2M or $0.28 per share, compared to a net loss of $5.1M or $0.18 per share for FY09. Net cash used in operating activities was $7.7M for FY10 compared to $4.3M for FY09.

 
BTX
4.24+0.04(+0.95%)11:47 AMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.